Literature DB >> 19704135

In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.

A Walkty1, M DeCorby, K Nichol, J A Karlowsky, D J Hoban, G G Zhanel.   

Abstract

The in vitro activity of colistin was evaluated versus 3,480 isolates of gram-negative bacilli using CLSI broth microdilution methods. The MIC(90) of colistin was < or = 2 microg/ml against a variety of clinically important gram-negative bacilli, including Escherichia coli, Klebsiella spp., Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. All multidrug-resistant (n = 76) P. aeruginosa isolates were susceptible to colistin (MIC, < or = 2 microg/ml). These data support a role for colistin in the treatment of infections caused by multidrug-resistant P. aeruginosa.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19704135      PMCID： PMC2772319          DOI： 10.1128/AAC.00786-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU.

Authors:  Hatem Kallel; Mabrouk Bahloul; Leila Hergafi; Malek Akrout; Wajdi Ketata; Hedi Chelly; Chokri Ben Hamida; Noureddine Rekik; Adnane Hammami; Mounir Bouaziz
Journal:  Int J Antimicrob Agents       Date:  2006-09-12       Impact factor: 5.283

Review 2.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

Review 3.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Authors:  Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

4.  The in-vitro activity of colistin in gram-negative bacteria.

Authors:  T Y Tan; S Y Ng
Journal:  Singapore Med J       Date:  2006-07       Impact factor: 1.858

5.  A reassessment of the in-vitro activity of colistin sulphomethate sodium.

Authors:  C R Catchpole; J M Andrews; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1997-02       Impact factor: 5.790

6.  Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.

Authors:  Pornpan Koomanachai; Surapee Tiengrim; Pattarachai Kiratisin; Visanu Thamlikitkul
Journal:  Int J Infect Dis       Date:  2007-02-08       Impact factor: 3.623

7.  Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

Authors:  J Garnacho-Montero; C Ortiz-Leyba; F J Jiménez-Jiménez; A E Barrero-Almodóvar; J L García-Garmendia; M Bernabeu-WittelI; S L Gallego-Lara; J Madrazo-Osuna
Journal:  Clin Infect Dis       Date:  2003-04-14       Impact factor: 9.079

8.  Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study.

Authors:  Rosa Reina; Elisa Estenssoro; Gabriela Sáenz; Héctor S Canales; Romina Gonzalvo; Gabriela Vidal; Gustavo Martins; Andrea Das Neves; Oscar Santander; Carlos Ramos
Journal:  Intensive Care Med       Date:  2005-06-28       Impact factor: 17.440

9.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

Authors:  A C Gales; R N Jones; H S Sader
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

10.  Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.

Authors:  Nikolaos Markou; Haralampos Apostolakos; Christiana Koumoudiou; Maria Athanasiou; Alexandra Koutsoukou; Ioannis Alamanos; Leonidas Gregorakos
Journal:  Crit Care       Date:  2003-07-28       Impact factor: 9.097
  10 in total
  20 in total

Review 1.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

2.  Polymyxin-resistant clinical isolates of Escherichia coli.

Authors:  Carl Urban; Hemavarna Tiruvury; Noriel Mariano; Rita Colon-Urban; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

Review 3.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

4.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 5.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

6.  Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007.

Authors:  Kyungwon Lee; Mi Ae Lee; Chae Hoon Lee; Jongwook Lee; Kyoung Ho Roh; Sunjoo Kim; Jin Ju Kim; Eunmi Koh; Dongeun Yong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

7.  Draft genome sequence of Paenibacillus polymyxa OSY-DF, which coproduces a lantibiotic, paenibacillin, and polymyxin E1.

Authors:  En Huang; Ahmed E Yousef
Journal:  J Bacteriol       Date:  2012-09       Impact factor: 3.490

8.  Carbapenem- and Colistin-Resistant Enterobacter cloacae from Delta, Colorado, in 2015.

Authors:  Andrew P Norgan; Jarred M Freese; Patricia M Tuin; Scott A Cunningham; Patricio R Jeraldo; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

9.  Evaluation of Chemical Changes in Laboratory-Induced Colistin-Resistant Klebsiella pneumoniae.

Authors:  Agata Pruss; Paweł Kwiatkowski; Łukasz Łopusiewicz; Helena Masiuk; Peter Sobolewski; Karol Fijałkowski; Monika Sienkiewicz; Adam Smolak; Stefania Giedrys-Kalemba; Barbara Dołęgowska
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

10.  Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.